Background: Numerous guidelines have been published for atopic dermatitis management in children in recent years. To date, the quality of the newest guidelines has not been appraised. Objective: To identify and evaluate guidelines for the management of atopic dermatitis in children. Design: A review of the guidelines for the management of atopic dermatitis in children and quality appraisal with AGREE II was conducted. Methods: We reviewed literature retrieved from PubMed, Web of Science, Ovid, ScienceDirect, Embase, China National Knowledge Infrastructure, WanFang Data, and guidelines websites. Search period from 1 January 2016 to 31 December 2021. The following keywords were used for searching: ‘atopic dermatitis’, ‘atopic eczema’, ‘eczema’, ‘guideline’ and ‘consensus’. The quality of the guidelines was assessed by two assessors using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) instrument independently, and domain scores were considered of sufficient quality when > 60%. Guidelines recommendations were reviewed. Results: Nineteen guidelines were included in the study. Three guidelines were graded A level that recommended for use in practice. Eleven guidelines were graded B level that recommended for use in revision. The remaining five guidelines were rated C level not as recommended. The average score of six domains of AGREE II was 64.76%, 48.53%, 42.35%, 73.83%, 32.23% and 70.17%, respectively. The consistency test showed that ICC ranged from 0.497 (95%CI: 0.105, 0.705) to 0.970 (95%CI: 0.93, 0.987) in the results of two assessors’ tests of the guidelines. Conclusions: Most guidelines were recommended for use with revision in the study. No major changes in primary management of atopic dermatitis in children compared to previous evidence. New biologic agents and complementary alternative medicine were increasingly available, but evidence for the treatment of atopic dermatitis in children was still limited.